

RESEARCH ARTICLE

Protection Induced in Broiler Chickens following Drinking-Water Delivery of Live Infectious Laryngotracheitis Vaccines against Subsequent Challenge with Recombinant Field Virus

Mesula G. Korsal¹, Glenn F. Browning¹, Mauricio J. C. Coppo¹, Alistair R. Legione¹, James R. Gilkerson¹, Amir H. Noormohammadi¹, Paola K. Vaz¹, Sang-Won Lee^{1,2}, Joanne M. Devlin¹✉*, Carol A. Hartley¹✉

1 The Asia-Pacific Centre for Animal Health, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, Australia, **2** College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea

✉ These authors contributed equally to this work.

* devlinj@unimelb.edu.au



OPEN ACCESS

Citation: Korsal MG, Browning GF, Coppo MJC, Legione AR, Gilkerson JR, Noormohammadi AH, et al. (2015) Protection Induced in Broiler Chickens following Drinking-Water Delivery of Live Infectious Laryngotracheitis Vaccines against Subsequent Challenge with Recombinant Field Virus. PLoS ONE 10(9): e0137719. doi:10.1371/journal.pone.0137719

Editor: Siba K Samal, University of Maryland, UNITED STATES

Received: July 17, 2015

Accepted: August 21, 2015

Published: September 14, 2015

Copyright: © 2015 Korsal et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by the Rural Industries Research and Development Corporation (RIRDC, PRJ-008792) and by the Australian Research Council (ARC, DP130103991). JMD is supported by an ARC Future Fellowship (FT140101287). The ARC had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The RIRDC contributed to the study design and approved the

Abstract

Infectious laryngotracheitis virus (ILTV) causes acute upper respiratory tract disease in chickens. Attenuated live ILTV vaccines are often used to help control disease, but these vaccines have well documented limitations, including retention of residual virulence, incomplete protection, transmission of vaccine virus to unvaccinated birds and reversion to high levels of virulence following bird-to-bird passage. Recently, two novel ILTV field strains (class 8 and 9 ILTV viruses) emerged in Australia due to natural recombination between two genotypically distinct commercial ILTV vaccines. These recombinant field strains became dominant field strains in important poultry producing areas. In Victoria, Australia, the recombinant class 9 virus largely displaced the previously predominant class 2 ILTV strain. The ability of ILTV vaccines to protect against challenge with the novel class 9 ILTV strain has not been studied. Here, the protection induced by direct (drinking-water) and indirect (contact) exposure to four different ILTV vaccines against challenge with class 9 ILTV in commercial broilers was studied. The vaccines significantly reduced, but did not prevent, challenge virus replication in vaccinated chickens. Only one vaccine significantly reduced the severity of tracheal pathology after direct drinking-water vaccination. The results indicate that the current vaccines can be used to help control class 9 ILTV, but also indicate that these vaccines have limitations that should be considered when designing and implementing disease control programs.

manuscript for publication, but had no role in data collection and analysis or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Infectious laryngotracheitis (ILT) is a contagious upper respiratory tract disease of chickens that causes significant economic losses in poultry industries around the world [1–3]. The disease is caused by an alphaherpesvirus, infectious laryngotracheitis virus (ILTV), which is classified taxonomically as *Gallidherpesvirus 1* [4]. In some outbreaks mortality rates of up to 70% have been reported [5]. Attenuated ILTV vaccines have been widely used to control the disease. However, these vaccines have several limitations, including insufficient attenuation [6], transmission of vaccine virus to unvaccinated birds [7,8], increased virulence after bird-to-bird transmission [9] and also incomplete protection in vaccinated birds [10,11].

Recently, two genetically distinct field strains (class 8 and 9 ILTV viruses) were detected in Australia using PCR-RFLP genotyping [12]. Evidence from whole genome sequence analysis of the three vaccine strains in use in Australia, along with the genome of these newly emerged strains, confirmed that the class 8 and 9 strains emerged as a result of natural (field) recombination between the recently introduced European-origin vaccine strain (Serva ILTV, MSD Animal Health) and the original Australian vaccine strains (SA-2 and A20 ILTV, Zoetis) [13]. The novel recombinant class 9 ILTV strain became the predominant field strain in important poultry producing regions in Victoria, Australia, largely displacing the previously dominant class 2 ILTVs [12] and continues to cause significant outbreaks of disease in commercial poultry flocks [13]. Recent studies have shown that, compared to class 2 ILTV, class 9 ILTV has enhanced replication kinetics, increased virulence and enhanced potential for horizontal transmission. These differences may help to explain the dominance of class 9 ILTV in the field [14].

Another factor that could contribute to the dominance of class 9 ILTV in the field is the extent to which the virus can be controlled using vaccination. The ability of vaccines to protect birds against challenge with class 9 ILTV has not been investigated previously. This study aimed to examine the extent to which four different live attenuated ILTV vaccines could protect commercial broiler birds against challenge with virulent class 9 ILTV. In order to remain relevant to field situations, this study aimed to use conditions similar to those that occur in the field, where possible.

Materials and Methods

Experimental design and virus strains used in this study

Approval for this study (Animal Ethics ID 1312956.1) was granted by the Animal Ethics Committee of the Faculty of Veterinary and Agricultural Sciences, The University of Melbourne. One hundred and twenty 10-day-old broilers (obtained from a commercial supplier at 1 day of age) were individually identified with numbered wing-tags and weighed on the day of vaccination (10 days old). Six groups of 20 birds each were placed in separate isolator units and were provided with feed and water *ad libitum*. Three groups were vaccinated with either Serva ILTV, SA-2 ILTV or A20 ILTV via drinking water according to manufacturers' instructions. A fourth group was similarly vaccinated with a glycoprotein G deleted candidate vaccine (Δ G ILTV) [15] via drinking water at a dose of 1.0×10^5 plaque forming units (PFU)/bird. The remaining two groups (negative and positive control groups) were mock vaccinated by addition of sterile cell culture medium to their drinking water. Immediately after vaccination, after the drinkers containing the vaccine had been removed from the isolators, five age-matched unvaccinated birds were added to each group. Twenty days after vaccination, all birds (including the contact-exposed birds) were inoculated with 1.0×10^3 PFU of virulent recombinant class 9 ILTV, except for the birds in the negative control group, which were mock-challenged with sterile cell culture medium. For challenge, half of the virus dose was inoculated into the

trachea and half of the dose was administered via eye-drop. The class 9 strain of ILTV had been propagated and titrated as described previously [16].

Four days after challenge, tracheal and conjunctival swabs were collected from all birds to assess viral replication. In addition, five birds that had been vaccinated directly in each group were selected at random and euthanised by exposure to an overdose of an inhalant anesthetic agent (halothane). These birds were weighed and proximal tracheal sections were collected and processed for histopathological examination as described previously [17]. Seven days after challenge all remaining birds were euthanized, weighed and samples collected as described above. The severity of virus-induced tracheal lesions, virus detection and replication in the trachea and conjunctiva, and body weight changes were used to assess protection.

Tracheal histopathology

Transverse sections of proximal trachea were collected, processed and stained with haematoxylin and eosin as described previously [14]. The severity of the histopathological lesions were scored from 0 (absent) to 4 (severe) as described previously [18] by two operators blinded to the group of origin of each of the sections.

Virus detection and quantification

DNA was extracted from tracheal and conjunctival swabs using the QIAextractor Vx virus kit (Qiagen) and a QIAextractor automated system (Qiagen) as described previously [14]. Positive and negative controls were included on each extraction plate. Infectious laryngotracheitis DNA was detected and quantified in the extracted DNA using real-time quantitative PCR and primers that amplify 113 bp of the UL15 gene of ILTV, as described previously [19]. A 10-fold dilution series of the UL15 sequence cloned into pGEM-T (Promega) was included in duplicate on each plate to enable estimation of the ILTV genome concentration in each of the extracted samples, with the lower limit of detection for the assay defined as 52 genome copies per reaction. Viral genome concentrations were \log_{10} transformed for statistical analysis.

Statistical analysis

Minitab 17 (Minitab Inc, 2010), GraphPad Prism 6 (GraphPad Prism Software) and Excel 2007 (Microsoft) were used to analyse data. Mann-Whitney tests were performed to compare the lesion scores determined by histopathological examination. One-way analyses of variance, in conjunction with Dunnett's Multiple Comparisons tests, were used to compare the viral genome concentrations and percentage body weight gains for the different groups. The normality assumption was assessed using normal probability plots, and equality of variance was checked using Levene's test. Fisher's exact test was used to compare the proportions of ILTV positive birds in each group. A two-tailed $p \leq 0.05$ was considered to be significant.

Results

Protection in broilers directly vaccinated via drinking water

Results from assays for virus detection and virus quantification, and tracheal histopathological examination in directly vaccinated birds, four days after challenge, are summarized in [Table 1](#). No significant differences in the severity of tracheal histopathological lesions were detected between groups. Viral genome concentrations were significantly lower in the tracheas of birds vaccinated with Serva, A20, SA-2 or Δ gG ILTV than is the unvaccinated-challenged (positive control) group. In contrast, viral genome concentrations in the conjunctiva did not differ significantly between any of the challenged groups. The proportion of birds in which virus was

Table 1. Results from assays for virus detection and virus quantification, and tracheal histopathological examination in birds directly vaccinated with different ILTV vaccines, four days after challenge .

Group		Median tracheal histopathology score (range)	Mean log ₁₀ viral genome copies/reaction ± S.D. [¶]		Proportion of birds positive for ILTV	
Vaccine	Challenge		Trachea	Conjunctiva	Trachea	Conjunctiva
None	None	1 (1–2) ^a	1.7 ± 0 ^a	1.7 ± 0 ^a	0/17 ^a	0/17 ^a
None	Class 9	2 (1–3) ^a	3.4 ± 2.2 ^b	1.8 ± 0.4 ^a	9/20 ^{b, c}	2/20 ^{a, c}
Serva	Class 9	2 (1–3) ^a	3 ± 1.8 ^a	1.9 ± 0.4 ^a	9/19 ^b	7/19 ^{b, c}
A20	Class 9	2 (1–3) ^a	1.8 ± 0.3 ^a	1.8 ± 0.2 ^a	3/20 ^{a, c}	5/20 ^{b, c}
SA-2	Class 9	2 (0–3) ^a	2.6 ± 0.9 ^a	1.7 ± 0 ^a	12/18 ^b	0/18 ^a
ΔgG	Class 9	2 (1–5) ^a	2.9 ± 2.0 ^a	1.8 ± 0.4 ^a	6/19 ^{b, c}	1/19 ^a

^{a,b,c} Values marked with the same superscripts in the same column were not significantly different ($p > 0.05$).

[¶] S.D = standard deviation. The lower limit of detection of the assay used to detect and quantify viral genome was 52, or 10^{1.72}, genome copies per reaction.

doi:10.1371/journal.pone.0137719.t001

detected in the conjunctiva and trachea varied between groups. Within the vaccinated groups, the lowest proportions of ILTV positive birds were seen in the group vaccinated with A20 ILTV (for detection of virus in the trachea) and in the group vaccinated with SA-2 ILTV (for detection of virus in the conjunctiva).

Results from assays for virus detection and virus quantification, and tracheal histopathological examination in directly vaccinated birds, seven days after challenge, are summarized in [Table 2](#). Birds that received the SA-2 ILTV vaccine had significantly less severe upper tracheal histopathology than birds in all other challenged groups. Viral genome concentrations were significantly lower in the tracheas of birds vaccinated with Serva, A20, SA-2 or ΔgG ILTV, than in birds in the unvaccinated-challenged (positive control) group. Viral genome concentrations were significantly lower in the conjunctivas of the birds vaccinated with Serva, A20 or SA-2 ILTV, than in those of the birds in the unvaccinated-challenged (positive control group). The proportion of birds in which virus was detected in the conjunctiva and trachea varied between groups. Within the vaccinated groups, the lowest proportions of ILTV positive birds were seen in the groups vaccinated with Serva or A20 ILTV (for detection of virus in the trachea) and in the group vaccinated with SA-2 ILTV (for detection of virus in the conjunctiva).

Table 2. Results from assays for virus detection and virus quantification, and tracheal histopathological examination in birds directly vaccinated with different ILTV vaccines, seven days after challenge.

Group		Median tracheal histopathology score (range)	Mean log ₁₀ viral genome copies/reaction ± S.D. [¶]		Proportion of birds positive for ILTV	
Vaccine	Challenge		Trachea	Conjunctiva	Trachea	Conjunctiva
None	None	2 (0–2) ^a	1.7 ± 0 ^a	1.7 ± 0 ^a	0/12 ^a	0/12 ^a
None	Class 9	3 (0–5) ^b	4.6 ± 1.9 ^b	2.9 ± 1.3 ^b	13/14 ^b	12/14 ^b
Serva	Class 9	3 (2–5) ^b	2.1 ± 0.9 ^a	1.9 ± 0.5 ^a	4/14 ^{a, c}	3/14 ^{a, c}
A20	Class 9	3 (1–5) ^b	2.1 ± 0.8 ^a	1.9 ± 0.4 ^a	4/15 ^{a, c}	3/15 ^{a, c}
SA-2	Class 9	1 (0–4) ^a	2.8 ± 1.3 ^a	1.7 ± 0 ^a	8/13 ^{b, c}	0/13 ^a
ΔgG	Class 9	3 (0–5) ^b	2.8 ± 1.6 ^a	2.8 ± 1.6 ^b	6/15 ^c	8/15 ^{c, b}

^{a,b,c} Values marked with the same superscripts in the same column were not significantly different ($p > 0.05$).

[¶] S.D = standard deviation. The lower limit of detection of the assay used to detect and quantify viral genome concentrations was 52, or 10^{1.72}, genome copies per reaction.

doi:10.1371/journal.pone.0137719.t002

Table 3. Percentage body weight changes between the day of vaccination and 20 days after vaccination, and between the day of challenge and days four and seven after challenge, in birds directly vaccinated with different ILTV vaccines.

Group		Mean percentage body weight change ± S.D [¶]					
Vaccine	Challenge	N	20 dpv	N	4 dpc	N	7 dpc
None	None	17	381 ± 64 ^a	5	27 ± 6 ^a	12	54 ± 8 ^a
None	Class 9	20	404 ± 91 ^a	5	15 ± 8 ^a	14	48 ± 15 ^a
Serva	Class 9	19	372 ± 98 ^a	5	33 ± 6 ^a	14	56 ± 8 ^a
A20	Class 9	20	414 ± 88 ^a	5	29 ± 12 ^a	15	50 ± 6 ^a
SA-2	Class 9	18	429 ± 84 ^a	5	30 ± 3 ^a	13	48 ± 14 ^a
ΔgG	Class 9	20	380 ± 80 ^a	5	28 ± 14 ^a	15	51 ± 17 ^a

^a Values marked with the same superscripts in the same column were not significantly different ($p > 0.05$).

[¶] SD = standard deviation, dpv = days post vaccination, dpc = days post challenge, N = number of birds.

doi:10.1371/journal.pone.0137719.t003

Percentage weight gains in directly vaccinated birds at three different time points (20 days after vaccination, four days after challenge and seven days after challenge) are summarized in [Table 3](#). No significant differences in percentage weight gain were detected between the groups at any of these time points.

Protection in broilers that were contact-exposed to vaccinated birds

The results from assays for virus detection and quantification four days after challenge in birds that were contact-exposed to vaccinated chickens, or contact-exposed to mock-vaccinated chickens in the negative and positive control groups, are summarized in [Table 4](#). No significant differences in viral genome concentration, or in the proportion of ILTV positive birds, were seen between groups.

Results from assays for virus detection and virus quantification, and tracheal histopathological examination seven days after challenge in birds that were contact-exposed to vaccinated birds are summarized in [Table 5](#). At this time after challenge, birds that were contact-exposed to chickens vaccinated with A20 or ΔgG ILTV had significantly less severe tracheal histopathology scores than birds that were contact exposed to mock vaccinated chickens in the positive control group. Furthermore, birds that were contact exposed to chickens vaccinated with

Table 4. The results from assays for viral detection and quantification four days after challenge in birds that were contact-exposed to vaccinated chickens.

Group		Mean log ₁₀ viral genome copies/ reaction ± S.D [¶]		Proportion of birds positive for ILTV	
Vaccine	Challenge	Trachea	Conjunctiva	Trachea	Conjunctiva
None	None	1.7 ± 0 ^a	1.7 ± 0 ^a	0/5 ^a	0/5 ^a
None	Class 9	3.3 ± 2.1 ^a	2.0 ± 0.6 ^a	3/5 ^a	1/5 ^a
Serva	Class 9	1.7 ± 0 ^a	1.7 ± 0.1 ^a	0/4 ^a	1/4 ^a
A20	Class 9	1.7 ± 0 ^a	1.7 ± 0 ^a	0/5 ^a	0/5 ^a
SA-2	Class 9	1.9 ± 0.4 ^a	1.7 ± 0 ^a	1/4 ^a	0/4 ^a
ΔgG	Class 9	4.0 ± 2.7 ^a	1.7 ± 0 ^a	2/4 ^a	0/4 ^a

^a Values marked with the same superscripts in the same column were not significantly different ($p > 0.05$).

[¶] S.D = standard deviation. The lower limit of detection of the assay used to detect and quantify viral genome was 52, or 10^{1.72}, genome copies per reaction.

doi:10.1371/journal.pone.0137719.t004

Table 5. Results from assays for virus detection and virus quantification, and tracheal histopathological examination seven days after challenge in birds that were contact-exposed to vaccinated chickens.

Group		Median tracheal histopathology score (range)	Mean log ₁₀ viral genome copies/reaction ± S.D [¶]		Proportions of birds positive for ILTV	
Vaccine	Challenge		Trachea	Conjunctiva	Trachea	Conjunctiva
None	None	1 (0–1) ^a	1.7 ± 0 ^a	1.7 ± 0 ^a	0/5 ^a	0/5 ^a
None	Class 9	4 (2–4) ^b	4.7 ± 0.9 ^b	3.1 ± 1.4 ^b	5/5 ^b	5/5 ^b
serva	Class 9	2 (2–4) ^{b, c}	1.9 ± 0.4 ^a	2.3 ± 1.1 ^{a, b}	1/4 ^a	1/4 ^a
A20	Class 9	2 (1–4) ^c	2.0 ± 0.6 ^a	2.1 ± 0.8 ^{a, b}	1/5 ^a	1/5 ^a
SA-2	Class 9	3.5 (1–5) ^{b, c}	1.7 ± 0 ^a	2.9 ± 0.8 ^b	0/4 ^a	3/4 ^b
ΔgG	Class 9	2.5 (1–4) ^c	4.7 ± 2 ^b	1.9 ± 0.3 ^{a, b}	3/4 ^b	1/4 ^a

^{a, b, c} Values marked with the same superscripts in the same column were not significantly different ($p > 0.05$).

[¶] S.D = standard deviation. The lower limit of detection of the assay used to detect and quantify viral genome was 52, or 10^{1.72}, genome copies per reaction.

doi:10.1371/journal.pone.0137719.t005

Serva, A20 or SA-2 ILTV had significantly lower ILTV genome concentrations in the trachea than birds that were contact exposed to mock vaccinated chickens in the positive control group. In contrast, no significant reduction in ILTV genome concentrations were seen in the conjunctiva of birds that were contact exposed to vaccinated chickens in any of the vaccinated groups, compared to birds that were contact exposed to mock-vaccinated chickens in the positive control group. The proportions of contact-exposed birds in which virus was detected in the conjunctiva and trachea varied between groups. Within the vaccinated groups, the lowest proportion of ILTV positive contact-exposed birds was in the SA-2 ILTV vaccinated group for detection of virus in the trachea, and in the A20, Serva and ΔgG ILTV vaccinated groups for detection of virus in the conjunctiva.

Percentage weight gains in birds contact-exposed to vaccinated chickens, at two different time points (20 days after vaccination and seven days after challenge) are summarized in Table 6. The only significant difference was in the group that were contact exposed to birds that received the A20 ILTV vaccine. This group had a significantly lower weight gain 20 days after vaccination compared with all other groups.

Table 6. Percentage body weight changes between the day of vaccination and 20 days after vaccination, and between the day of challenge and day seven after challenge, in birds that were contact exposed to vaccinated chickens.

Group		Mean percentage body weight change ± S.D [¶]			
Vaccine	Challenge	N	20 dpv	N	7 dpc
None	None	5	350 ± 37 ^a	5	53 ± 9 ^a
None	Class 9	5	329 ± 42 ^a	5	49 ± 14 ^a
Serva	Class 9	4	358 ± 57 ^a	4	61 ± 10 ^a
A20	Class 9	5	309 ± 67 ^b	5	51 ± 9 ^a
SA-2	Class 9	4	393 ± 64 ^a	4	47 ± 4 ^a
ΔgGV	Class 9	4	401 ± 142 ^a	4	36 ± 16 ^a

^{a, b}. Values marked with the same superscript in the same column at a given time point were not significantly different ($p > 0.05$).

[¶] S.D = standard deviation, dpv = days post vaccination, dpc = days post challenge, N = number of birds.

doi:10.1371/journal.pone.0137719.t006

Discussion

This study aimed to evaluate the ability of attenuated ILTV vaccines to control recombinant, class 9 ILTV under conditions similar to those that occur in the field. Importantly we applied the vaccine via drinking water. Drinking water vaccination is a preferred method for mass delivery of vaccine to large broiler flocks due to the ease and cost effectiveness of application. However, under field conditions, some birds may not consume drinking water containing the vaccine, or may receive a suboptimal dose of the vaccine because of reduced consumption. These birds, therefore, remain either unvaccinated or incompletely vaccinated [10,11,20]. Other factors may also limit the effectiveness of vaccines delivered via drinking water in poultry, including equipment limitations, poor water quality and sub-optimal preparation and handling of the vaccine [21]. The birds that are not fully vaccinated by drinking water may become infected with vaccine virus following horizontal transmission from vaccinated birds [22], or may remain naïve, creating a small susceptible population within the flock. In order to simulate the lack of uniform vaccination that can occur in commercial flocks vaccinated by drinking water, the present study included five unvaccinated, age-matched birds that were placed in-contact with vaccinated birds in each of the groups immediately after vaccination. Their subsequent protection against challenge with virulent virus was assessed. This challenge virus was administered via intra-tracheal inoculation and via eye-drop in order to simulate the respiratory and ocular routes of infection that occur under field conditions [5].

The study used commercial broiler chickens, instead of specific-pathogen free (layer-type) chickens, in order to ensure its relevance to field situations and commercial broiler industries. Previous studies have demonstrated immunological differences between broiler and layer types of chickens. Broilers produce a strong short-term humoral response, whereas layer-type chickens produce a long-term humoral response in conjunction with a stronger cellular response. These features in broilers appear to be a consequence of genetic selection for economically important traits [23]. In this study birds were vaccinated at 10 days of age, consistent with common field vaccination practices in Australia, and challenged at 30 days of age, an age at which ILT outbreaks have commonly been seen in broilers in Australia [22]. Age at vaccination and age at challenge are important parameters that can influence protection and disease expression. Previous studies have shown poorer immune responses in chickens vaccinated before two weeks of age due to the immaturity of their cell-mediated immunity, rather than effects of maternally derived antibodies, which are not protective against ILTV [24,25]. However the short growth cycle in commercial broiler production systems often requires vaccinations to be performed at a younger age than would be immunologically ideal, and so we used a younger age of vaccination in this study. As antibodies are not protective against ILTV this study did not assess serum antibody levels in the vaccinated chickens.

The results from our study showed that, under conditions resembling field conditions, all the attenuated vaccines induced a level of protection against challenge with recombinant class 9 ILTV in chickens directly vaccinated via drinking water. All vaccines reduced the amount of detectable virus in the trachea at both four and seven days after challenge compared to unvaccinated birds. All vaccines also reduced the proportion of birds that were positive for the presence of ILTV DNA in conjunctival and/or tracheal swabs seven days after challenge. Furthermore the SA-2, A20 and Serva ILTV vaccines reduced the amount of virus detected in the conjunctiva seven days after challenge. Reducing the level of virus replication within flocks is important for the control of ILT, as this is likely to reduce the viral load in the environment and potentially decrease the risk of spread beyond the infected flock to new flocks or farms. However it is important to note that this study only assessed viral load using qPCR detection of viral DNA, which is unable to discriminate between viable and unviable virus [17]. Detection

of viable virus would require virus isolation in either cell culture or embryonated eggs, however this can be impractical in large studies such as this current study. Also the qPCR assay did not discriminate between DNA from the challenge virus and DNA from vaccine viruses. It is possible that some DNA from the vaccine viruses may have been detectable after challenge. The future development of new diagnostic tools to differentiate and quantitate vaccine and challenge viruses present in mixed infections would be beneficial for investigating this further.

Interestingly, only SA-2 ILTV reduced the severity of tracheal lesions following challenge. Although the SA-2 ILTV strain is known to be highly immunogenic, it is also less attenuated than some other ILTV vaccines, so it is not normally recommended for use in broilers because of concerns about its safety in these birds [15,17,26]. No significant vaccine safety concerns were noted in this study following SA-2 inoculation, however in the field factors such as stocking rates, housing conditions, and concurrent infection with other pathogens may influence disease expression.

In contact-exposed birds, all groups of birds that were contact-exposed to vaccinated chickens showed some degree of protection against challenge compared to birds that were grouped with unvaccinated chickens. This contrasts with a previous study from the USA [27] in which none of the contact-exposed birds were protected against challenge. The differing outcomes of our study and this previous study could be due to differences in the challenge and vaccine strains used between studies and also differences in experimental design, particularly the ratio of in-contact birds to directly vaccinated birds (1:1 in the previous study, 1:4 in this study) that may have created conditions more favourable for transmission of vaccine virus from directly vaccinated to contact-exposed in our study. In our study, this protection was only seen seven days after challenge and included reduced levels of tracheal pathology (in birds contact-exposed to A20 or ΔgG ILTV vaccinated chickens), reduced concentrations of detectable viral DNA in the trachea (in birds contact-exposed to Serva, A20 or SA-2 ILTV vaccinated chickens) or reduced proportions of birds that had detectable ILTV DNA in conjunctival and/or tracheal swabs (in birds contact-exposed to Serva, A20, SA-2 or ΔgG ILTV vaccinated chickens). This protection was presumably due to horizontal transmission of vaccine virus from directly-vaccinated birds to in-contact birds, although this transmission was not directly assessed. Although transmission of vaccine virus to naïve birds can have potential benefits in terms of inducing a level of protection against challenge, there is also potential for some vaccine strains of virus to revert to higher levels of virulence following bird-to-bird passage [8,9] or the potential for their involvement in recombination events with other strains of ILTV [13]. For these reasons field vaccination programs strive to achieve optimal, direct vaccination of all birds to generate uniform protection.

Unexpectedly, no significant difference was seen in percentage weight gain between groups directly vaccinated with the different vaccines in this study. This is in contrast to results from a previous study of class 9 ILTV in which unvaccinated-challenged birds had significantly decreased weight gain, compared to negative control birds at 6 days after challenge [14]. This could be explained by the different environmental conditions that were required for this present study. In particular, light intensity and duration were restricted in order to facilitate the control of aggressive (pecking) behavior seen in some of the chickens. This pecking behavior also necessitated euthanasia (using halothane) of some birds in order to ameliorate suffering, in accordance with animal ethics approval for this work. This resulted in different numbers of birds per group at some time points. In broiler chickens, light restriction programs have been shown to decrease weight gain [28] and so it is possible that these measures to control pecking also restricted weight gain. This may have prevented differences in weight gain between groups being expressed.

In the unvaccinated-challenged birds the assay for virus detection and quantification, and tracheal histopathological examination, revealed some apparent differences in viral replication and disease progression associated with class 9 ILTV compared to another strain of ILTV (CSW-1 ILTV) assessed in previous studies. Following inoculation of class 9 ILTV, the highest viral genome concentrations were seen in the trachea seven days after challenge. The proportions of ILTV positive birds were also highest seven days after challenge and tracheal lesions were most severe seven days after challenge. In studies utilizing the CSW-1 strain of ILTV (a virulent field virus commonly used as an experimental challenge strain in Australia), tracheal pathology and virus replication reach their highest levels four days after challenge, with most virus cleared from the tracheal mucosa by seven days after challenge [15]. The results from this study, in conjunction with previously reported results showing the presence of tracheal pathology and virus replication up to 21 days after infection with class 9 ILTV [14], suggest that the duration of infection and disease is extended for class 9 ILTV. This could be linked to the dominance of class 9 ILTV in the field.

Taken together the results from this study indicate that the currently available attenuated vaccines and the glycoprotein G deleted candidate vaccine can be used to help control class 9 ILTV when delivered by drinking water. However it is important to note that neither the protection induced in the directly-vaccinated birds, nor that induced in birds that were contact-exposed to vaccinated birds, was complete. This may help to explain the persistence of class 9 ILTV infection and disease in commercial poultry flocks of Australia, despite the widespread use of vaccination programs similar to those employed in this study. The results highlight the wisdom of combining vaccination programs with other disease control measures, such as biosecurity measures, in order to improve ILTV control. Our study also highlights the need to continue to seek improvements in ILTV vaccines and vaccine delivery methods in order to achieve improved protection against challenge with virulent virus.

Acknowledgments

The authors gratefully acknowledge statistical assistance provided by Prof. Mark Stevenson and Dr. Simon Firestone (The University of Melbourne) and thank Cheryl Colson and June Daly for the care of the animals.

Author Contributions

Conceived and designed the experiments: SWL JMD CAH GFB AHN. Performed the experiments: MGK MJCC ARL JRG AHN PKV JMD CAH. Analyzed the data: MGK MJCC JMD CAH. Contributed reagents/materials/analysis tools: JMD MJCC. Wrote the paper: MGK MJCC ARL GFB AHN PKV JMD CAH SWL.

References

1. Bagust TJ, Laryngotracheitis (Gallid-1) herpesvirus infection in the chicken. 4. Latency establishment by wild and vaccine strains of ILT virus. *Avian Pathol.* 1986; 15: 581–595. PMID: [18766556](#)
2. Bagust TJ, Jones RC, Guy JS. Avian infectious laryngotracheitis. *Rev Sci Tech.* 2000; 19: 483–492. PMID: [10935275](#)
3. Jones RC. Viral respiratory diseases (ILT, AMPV infections, IB): are they ever under control? *Bri Poult Sci.* 2010; 51: 1–11.
4. Davison AJ, Herpesvirus systematics. *Vet Microbiol.* 2010; 143: 52–69. doi: [10.1016/j.vetmic.2010.02.014](#) PMID: [20346601](#)
5. Fuchs W, Veits J, Helferich D, Granzow H, Teifke JP, Mettenleiter TC. Molecular biology of avian infectious laryngotracheitis virus. *Vet Research.* 2007; 38: 261–279.

6. Oldoni I, Rodríguez-Avila A, Riblet SM, Zavala G, García M. Pathogenicity and growth characteristics of selected infectious laryngotracheitis virus strains from the United States. *Avian Pathol.* 2009; 38: 47–53. doi: [10.1080/03079450802632031](https://doi.org/10.1080/03079450802632031) PMID: [19156579](https://pubmed.ncbi.nlm.nih.gov/19156579/)
7. Neff C, Sudler C, Hoop RK. Characterization of Western European Field Isolates and Vaccine Strains of Avian Infectious Laryngotracheitis Virus by Restriction Fragment Length Polymorphism and Sequence Analysis. *Avian Dis.* 2008; 52: 278–283. PMID: [18646457](https://pubmed.ncbi.nlm.nih.gov/18646457/)
8. Oldoni I, Rodríguez-Avila A, Riblet S, García M. Characterization of Infectious Laryngotracheitis Virus (ILTV) Isolates from Commercial Poultry by Polymerase Chain Reaction and Restriction Fragment Length Polymorphism (PCR-RFLP). *Avian Dis.* 2008; 52: 59–63. PMID: [18459297](https://pubmed.ncbi.nlm.nih.gov/18459297/)
9. Guy JS, Barnes HJ, Smith L. Increased virulence of modified-live infectious laryngotracheitis vaccine virus following bird-to-bird passage. *Avian Dis.* 1991; 35: 348–355. PMID: [1649591](https://pubmed.ncbi.nlm.nih.gov/1649591/)
10. Fulton R, Schrader D, Will M. Effect of route of vaccination on the prevention of infectious laryngotracheitis in commercial egg-laying chickens. *Avian Dis.* 2000; 44: 8–16. PMID: [10737639](https://pubmed.ncbi.nlm.nih.gov/10737639/)
11. Coppo MJC, Devlin JM, Noormohammadi AH. Comparison of the replication and transmissibility of an infectious laryngotracheitis virus vaccine delivered via eye-drop or drinking-water. *Avian Pathol.* 2012; 41: 99–106. doi: [10.1080/03079457.2011.643222](https://doi.org/10.1080/03079457.2011.643222) PMID: [22845327](https://pubmed.ncbi.nlm.nih.gov/22845327/)
12. Blacker HP, Kirkpatrick NC, Rubite A, O'Rourke D, Noormohammadi AH. Epidemiology of recent outbreaks of infectious laryngotracheitis in poultry in Australia. *Aus Vet J.* 2011; 89: 89–94.
13. Lee SW, Markham PF, Coppo MJ, Legione AR, Markham JF, Noormohammadi AH, et al. Attenuated vaccines can recombine to form virulent field viruses. *Science.* 2012; 337: 188. doi: [10.1126/science.1217134](https://doi.org/10.1126/science.1217134) PMID: [22798607](https://pubmed.ncbi.nlm.nih.gov/22798607/)
14. Lee S-W, Hartley CA, Coppo M, Vaz PK, Legione AR, Quinteros JA, et al. Growth Kinetics and Transmission Potential of Existing and Emerging Field Strains of Infectious Laryngotracheitis Virus. *PLoS One.* 2015; 10:e0120282. doi: [10.1371/journal.pone.0120282](https://doi.org/10.1371/journal.pone.0120282) PMID: [25785629](https://pubmed.ncbi.nlm.nih.gov/25785629/)
15. Devlin JM, Browning GF, Hartley CA, Gilkerson JR. Glycoprotein G deficient infectious laryngotracheitis virus is a candidate attenuated vaccine. *Vaccine.* 2007; 25: 3561–3566. PMID: [17316926](https://pubmed.ncbi.nlm.nih.gov/17316926/)
16. Lee S, Markham PF, Coppo MJC, Legione AR, Shil NK, Quinteros JA, et al. Cross-protective immune responses between genotypically distinct lineages of infectious laryngotracheitis viruses. *Avian Dis.* 2014; 58: 147–152. PMID: [24758128](https://pubmed.ncbi.nlm.nih.gov/24758128/)
17. Coppo MJ, Noormohammadi AH, Hartley CA, Gilkerson JR, Browning GF, Devlin JM. Comparative in vivo safety and efficacy of a glycoprotein G-deficient candidate vaccine strain of infectious laryngotracheitis virus delivered via eye drop. *Avian Pathol.* 2011; 40: 411–417. doi: [10.1080/03079457.2011.588686](https://doi.org/10.1080/03079457.2011.588686) PMID: [21812721](https://pubmed.ncbi.nlm.nih.gov/21812721/)
18. Guy JS, Barnes HJ, Morgan LM. Virulence of infectious laryngotracheitis viruses: comparison of modified-live vaccine viruses and North Carolina field isolates. *Avian Dis.* 1990; 34: 106–113. PMID: [2157386](https://pubmed.ncbi.nlm.nih.gov/2157386/)
19. Mahmoudian A, Kirkpatrick NC, Coppo M, Lee S-W, Devlin JM, Markham PF, et al. Development of a SYBR Green quantitative polymerase chain reaction assay for rapid detection and quantification of infectious laryngotracheitis virus. *Avian Pathol.* 2011; 40: 237–242. doi: [10.1080/03079457.2011.553582](https://doi.org/10.1080/03079457.2011.553582) PMID: [21711182](https://pubmed.ncbi.nlm.nih.gov/21711182/)
20. Robertson G, Egerton J. Replication of infectious laryngotracheitis virus in chickens following vaccination. *Aus Vet J.* 1981; 57: 119–123.
21. Mutinda WU, Nyaga PN, Mbuthia PG, Bebora LC, Muchemi G. Risk factors associated with infectious bursal disease vaccination failures in broiler farms in Kenya. *Trop Anim Health Prod.* 2014; 46: 603–608. doi: [10.1007/s11250-013-0533-x](https://doi.org/10.1007/s11250-013-0533-x) PMID: [24414247](https://pubmed.ncbi.nlm.nih.gov/24414247/)
22. Devlin JM, Hartley CA, Gilkerson JR, Coppo MJC, Vaz P, Noormohammadi AH, et al. Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmission of virulent virus. *Vaccine.* 2011; 29: 5699–5704. doi: [10.1016/j.vaccine.2011.06.002](https://doi.org/10.1016/j.vaccine.2011.06.002) PMID: [21689710](https://pubmed.ncbi.nlm.nih.gov/21689710/)
23. Koenen ME, Boonstra-Blom AG, Jeurissen SH. Immunological differences between layer-and broiler-type chickens. *Vet Immunol Immunop.* 2002; 89: 47–56.
24. Cover M, Benton W, Krauss W. The effect of parental immunity and age on the response to infectious laryngotracheitis vaccination. *Avian Dis.* 1960; 4: 467–473.
25. Gharaibeh S, Mahmoud K. Decay of maternal antibodies in broiler chickens. *Poult Sci.* 2013; 92: 2333–2336. doi: [10.3382/ps.2013-03249](https://doi.org/10.3382/ps.2013-03249) PMID: [23960115](https://pubmed.ncbi.nlm.nih.gov/23960115/)
26. Purcell D, Surman P. Aerosol administration of the SA-2 vaccine strain of infectious laryngotracheitis virus. *Aus Vet J.* 1974; 50: 419–420.
27. Rodríguez-Avila A, Oldoni I, Riblet S, García M. Evaluation of the protection elicited by direct and indirect exposure to live attenuated infectious laryngotracheitis virus vaccines against a recent challenge

strain from the United States. *Avian Pathol.* 2008; 37: 287–292. doi: [10.1080/03079450802043742](https://doi.org/10.1080/03079450802043742)
PMID: [18568655](https://pubmed.ncbi.nlm.nih.gov/18568655/)

28. Ingram D, Hattens L, McPherson B. Effects of light restriction on broiler performance and specific body structure measurements. *J Applied Poultry Res.* 2000; 9: 501–504.



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Korsa, MG; Browning, GF; Coppo, MJC; Legione, AR; Gilkerson, JR; Noormohammadi, AH; Vaz, PK; Lee, S-W; Devlin, JM; Hartley, CA

Title:

Protection Induced in Broiler Chickens following Drinking-Water Delivery of Live Infectious Laryngotracheitis Vaccines against Subsequent Challenge with Recombinant Field Virus

Date:

2015-09-14

Citation:

Korsa, M. G., Browning, G. F., Coppo, M. J. C., Legione, A. R., Gilkerson, J. R., Noormohammadi, A. H., Vaz, P. K., Lee, S. -W., Devlin, J. M. & Hartley, C. A. (2015). Protection Induced in Broiler Chickens following Drinking-Water Delivery of Live Infectious Laryngotracheitis Vaccines against Subsequent Challenge with Recombinant Field Virus. PLOS ONE, 10 (9), <https://doi.org/10.1371/journal.pone.0137719>.

Persistent Link:

<http://hdl.handle.net/11343/102420>

File Description:

Published version

License:

CC BY